| The potential and controversy of targeting STAT family members in cancer Y Verhoeven, S Tilborghs, J Jacobs, J De Waele, D Quatannens, ... Seminars in cancer biology 60, 41-56, 2020 | 278 | 2020 |
| CD70: An emerging target in cancer immunotherapy J Jacobs, V Deschoolmeester, K Zwaenepoel, C Rolfo, K Silence, ... Pharmacology & therapeutics 155, 1-10, 2015 | 187 | 2015 |
| Cold atmospheric plasma-treated PBS eliminates immunosuppressive pancreatic stellate cells and induces immunogenic cell death of pancreatic cancer cells J Van Loenhout, T Flieswasser, L Freire Boullosa, J De Waele, ... Cancers 11 (10), 1597, 2019 | 95 | 2019 |
| Immune checkpoint modulation in colorectal cancer: what’s new and what to expect J Jacobs, E Smits, F Lardon, P Pauwels, V Deschoolmeester Journal of immunology research 2015, 2015 | 90 | 2015 |
| Circulating cell-free DNA and RNA analysis as liquid biopsy: optimal centrifugation protocol L Sorber, K Zwaenepoel, J Jacobs, K De Winne, S Goethals, P Reclusa, ... Cancers 11 (4), 458, 2019 | 87 | 2019 |
| The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer C Deben, A Wouters, KO de Beeck, J van Den Bossche, J Jacobs, ... Oncotarget 6 (26), 22666, 2015 | 77 | 2015 |
| Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer J Jacobs, K Zwaenepoel, C Rolfo, J Van den Bossche, C Deben, ... Oncotarget 6 (15), 13462, 2015 | 73 | 2015 |
| The CD70-CD27 axis in oncology: the new kids on the block T Flieswasser, A Van den Eynde, J Van Audenaerde, J De Waele, ... Journal of experimental & clinical cancer research 41 (1), 12, 2022 | 69 | 2022 |
| CD 70 and PD‐L1 in anaplastic thyroid cancer–promising targets for immunotherapy K Zwaenepoel, J Jacobs, A De Meulenaere, K Silence, E Smits, ... Histopathology 71 (3), 357-365, 2017 | 63 | 2017 |
| Hypoxia-induced cisplatin resistance in non-small cell lung cancer cells is mediated by HIF-1α and mutant p53 and can be overcome by induction of oxidative stress C Deben, V Deschoolmeester, J De Waele, J Jacobs, J Van den Bossche, ... Cancers 10 (4), 126, 2018 | 55 | 2018 |
| APR-246 (PRIMA-1MET) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines C Deben, F Lardon, A Wouters, KO de Beeck, J Van den Bossche, ... Cancer letters 375 (2), 313-322, 2016 | 55 | 2016 |
| Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation J Jacobs, V Deschoolmeester, K Zwaenepoel, T Flieswasser, C Deben, ... Oncoimmunology 7 (7), e1440167, 2018 | 46 | 2018 |
| Clinically relevant chemotherapeutics have the ability to induce immunogenic cell death in non-small cell lung cancer T Flieswasser, J Van Loenhout, L Freire Boullosa, A Van den Eynde, ... Cells 9 (6), 1474, 2020 | 43 | 2020 |
| Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: Investigation of the role of cetuximab sensitivity and HPV status H Baysal, I De Pauw, H Zaryouh, J De Waele, M Peeters, P Pauwels, ... British Journal of Cancer 123 (5), 752-761, 2020 | 34 | 2020 |
| Specialized blood collection tubes for liquid biopsy: improving the pre-analytical conditions L Sorber, K Zwaenepoel, J Jacobs, K De Winne, K Van Casteren, ... Molecular Diagnosis & Therapy 24 (1), 113-124, 2020 | 31 | 2020 |
| Deep sequencing of the TP53 gene reveals a potential risk allele for non–small cell lung cancer and supports the negative prognostic value of TP53 variants C Deben, J Van den Bossche, N Van Der Steen, F Lardon, A Wouters, ... Tumor Biology 39 (2), 1010428317694327, 2017 | 30 | 2017 |
| RANK-RANKL signaling in cancer of the uterine cervix: a review PA Van Dam, Y Verhoeven, J Jacobs, A Wouters, W Tjalma, F Lardon, ... International journal of molecular sciences 20 (9), 2183, 2019 | 28 | 2019 |
| Screening a broad range of solid and haematological tumour types for CD70 expression using a uniform IHC methodology as potential patient stratification method T Flieswasser, V Camara-Clayette, A Danu, J Bosq, V Ribrag, P Zabrocki, ... Cancers 11 (10), 1611, 2019 | 27 | 2019 |
| Mass spectrometry imaging reveals neutrophil defensins as additional biomarkers for anti-PD-(L) 1 immunotherapy response in NSCLC patients E Berghmans, J Jacobs, C Deben, C Hermans, G Broeckx, E Smits, ... Cancers 12 (4), 863, 2020 | 23 | 2020 |
| In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53 J Van den Bossche, C Deben, I De Pauw, H Lambrechts, C Hermans, ... Molecular Oncology 13 (5), 1196-1213, 2019 | 20 | 2019 |
